ABSTRACT
Los tumores retroperitoneales representan un 0,07 a 0,2% de todas las neoplasias del organismo. Los liposarcomas, formas predominantes de sarcomas, se originan del mesodermo embrionario y pueden alcanzar grandes dimensiones en el retroperitoneo, presentándose en forma de masas voluminosas sin sintomatología específica. Las metástasis a distancia son poco probables; la mortalidad específica es del 40 al 50% a los 5 años del diagnóstico y su pronóstico depende de su variedad histopatológica. La conducta es quirúrgica y consiste en exéresis radical del tumor; junto con la radioterapia y la quimioterapia como tratamiento paliativo. Se presenta un caso del liposarcoma retroperitoneal gigante bien diferenciado de células fusiformes; manifestado por distensión abdominal progresiva acompañado de dolor tipo opresivo de moderada intensidad y el tratamiento efectuado, la resección quirúrgica radical.
The retroperitoneal tumors represent 0.07 to 0.2% of all neoplasias.The liposarcomas are predominant forms of sarcomas, they can reach big size in the retroperitoneum, and they show like voluminous mass without specific symptomatology. The metastasis is improbable; the specific mortality is from 40 to 50% in 5 years since the diagnostic, and the prognostic depends of the histopathologic variety. The conduct is surgical and this consists in radical excision of the tumor, together with radiotherapy and chemotherapy, like palliative treatments. We present a case of giant retroperitoneal liposarcoma, differentiated of fusiforms cells; it is shown as a progressive abdominal distension with oppressive pain of moderate intensity; and the treatment effectuated was the radical surgical excision.
ABSTRACT
The identification of mycobacterial species in clinical isolates is essential for making patient care decisions. Polymerase chain reaction (PCR) restriction enzyme analysis (PRA) is a simple and rapid identification method, based on amplification of 441 bp of the hsp65 gene and restriction with BstEII and HaeIII. As a contribution to the validation of PRA, a multicenter study was performed in eight laboratories located in Argentina, Brazil, Colombia, Chile, and Guadeloupe. Each laboratory received 18 coded isolates from the collection of the Institute of Tropical Medicine (Antwerp, Belgium), representing duplicates of nine laboratory strains: Mycobacterium terrae CIPT 140320001, Mycobacterium scrofulaceum CIPT 140220031, Mycobacterium flavescens ATCC 14474, Mycobacterium triviale ATCC 23292, Mycobacterium nonchromogenicum ATCC 19530, Mycobacterium chitae ATCC 19627, Mycobacterium abscessus ATCC 19977, Mycobacterium kansasii ATCC 12478, and Mycobacterium peregrinum ATCC 14467. A detailed protocol including amplification, enzymatic digestion, and gel preparation was provided to each laboratory. Two laboratories identified correctly all 18 (100%) isolates, one identified correctly 17 (94.5%), two identified 14 (77.7%), one identified 11 (61%), and two identified 8 (44.4%) isolates. Errors detected in laboratories with more than 77% accuracy were associated with electrophoresis running conditions and an unspecific amplicon produced by a single strain. Lower accuracy was mainly related to inappropriate use of DNA markers and insufficient training in interpretation of patterns. In conclusion, the PRA method was readily implemented in some Latin American and Caribbean laboratories of mycobacteria, but improvements in critical points, as gel running conditions and training in interpretiation of patterns, are needed in order to improve accuracy. In others, improvement in critical points is still necessary.
